![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1681377
¼¼°èÀÇ Æú¸® Ä«Å×ÅÍ ½ÃÀå ±Ô¸ð ºÐ¼® : Á¦Ç°º°, Àç·áº°, ÀûÀÀÁõº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)Global Foley Catheter Market Size Study, by Product, by Material, by Indication, by End Use, and Regional Forecasts 2022-2032 |
¼¼°èÀÇ Æú¸® Ä«Å×ÅÍ ½ÃÀåÀº 2023³â¿¡ ¾à 17¾ï 4,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024-2032³â¿¡ CAGR 5.86%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ºñ´¢±â ÁúȯÀÇ À¯º´·ü Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡, ÃÖ¼Òħ½À¼ö¼ú(MIS)¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡, Ä«Å×ÅÍ ±â¼úÀÇ ¹ßÀüÀÔ´Ï´Ù.
¿ä·Î°¨¿°(UTI), ½ÅÀåÁúȯ, Àü¸³¼±ºñ´ëÁõ(BPH)ÀÇ ¹ß»ý·ü Áõ°¡·Î ÀÎÇØ È¿°úÀûÀÎ ¿äµµ°ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ½ÅÀåÀç´Ü(2023³â)¿¡ µû¸£¸é ³²¼ºÀÇ ¾à 19.1%, ¿©¼ºÀÇ ¾à 9.4%°¡ 70¼¼±îÁö ½ÅÀå °á¼®À» °æÇèÇϰí ÀÖÀ¸¸ç, ÀÌ´Â Æú¸®Ä«Å×ÅÍ¿Í °°Àº Àå±âÀûÀÎ ¹è´¢ °ü¸® ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ º¸°í¿¡ µû¸£¸é Àü ¼¼°è¿¡¼ 1,500¸¸ ¸í ÀÌ»óÀÌ Ã´¼ö¼Õ»ó(SCI)À» ¾Î°í ÀÖÀ¸¸ç, ±× Áß »ó´ç¼ö°¡ ¹æ±¤ °ü¸®¸¦ À§ÇØ ¿äµµ»ðÀÔ Ä«Å×Å͸¦ ÇÊ¿ä·Î Çϰí ÀÖ½À´Ï´Ù.
ÀÛÀº Àý°³Ã¢, ªÀº ÀÔ¿ø±â°£, ºü¸¥ ȸº¹À» À§ÇØ È¯ÀÚµéÀº ÃÖ¼Òħ½À¼ö¼ú(MIS)À» ¼±È£Çϰí ÀÖÀ¸¸ç, ÀÌ¿¡ µû¶ó MIS ¼ö¼úÀÇ Ã¤ÅÃÀÌ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. Æú¸® Ä«Å×ÅÍ´Â MIS ¼ö¼ú¿¡¼ Áö¼ÓÀûÀÎ ¹æ±¤ ¹è¾×À» Á¦°øÇÏ°í ¼ö¼ú ÈÄ ÇÕº´ÁõÀ» ÁÙÀÌ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¶ÇÇÑ Ç×±Õ ÄÚÆÃ, ¼¾¼°¡ ÀåÂøµÈ ½º¸¶Æ® Ä«Å×ÅÍ, »ýºÐÇØ¼º ¼ÒÀç µîÀÇ ±â¼ú ¹ßÀüÀº Æú¸®Ä«Å×ÅÍÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» Çâ»ó½ÃÄÑ ½ÃÀå ¼ºÀåÀ» ´õ¿í °¡¼ÓȽÃ۰í ÀÖ½À´Ï´Ù.
¾÷°è ÁÖ¿ä ±â¾÷ °£ÀÇ Àü·«Àû Á¦ÈÞ ¹× M&A Ȱµ¿ÀÌ °æÀï ±¸µµ¸¦ Çü¼ºÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 12¿ù Bactiguard Holding AB´Â BD(Becton Dickinson &Company)¿Í Á¦ÈÞÇÏ¿© ¹Ì±¹, ij³ª´Ù, ¿µ±¹, ¾ÆÀÏ·£µå, ÀϺ», È£ÁÖ¸¦ Æ÷ÇÔÇÑ ¿©·¯ ±¹°¡¿¡¼ Bactiguard ÄÚÆÃ Æú¸® Ä«Å×Å͸¦ ÆÇ¸ÅÇÏ°Ô µÇ¾ú½À´Ï´Ù. ÆÇ¸ÅÇÏ°Ô µÇ¾ú½À´Ï´Ù. À̹ø ÆÇ¸Å °è¾àÀº ½ÃÀå ħÅõ¸¦ È®´ëÇÏ°í ¸ÅÃâ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.
Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â 31.62%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, À̴ ÷´Ü ÀÇ·á ÀÎÇÁ¶ó, ¸¸¼º ½ÅÀåÁúȯ(CKD) À¯º´·ü Áõ°¡, ³ôÀº °í·ÉÈÀ²¿¡ ±âÀÎÇÑ °ÍÀ¸·Î ºÐ¼®µË´Ï´Ù. ±×·¯³ª ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·áºñ Áõ°¡, Áß±¹°ú ÀϺ»ÀÇ ±Þ¼ÓÇÑ °í·ÉÈ, ºñ´¢±â°ú ÀÇ·á¿¡ ´ëÇÑ Á¢±Ù¼º È®´ë¿¡ ÈûÀÔ¾î °¡Àå ºü¸¥ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
The global foley catheter market was valued at approximately USD 1.74 billion in 2023 and is projected to grow at a CAGR of 5.86% from 2024 to 2032. Market growth is fueled by the increasing prevalence of urological disorders, a growing geriatric population, rising preference for minimally invasive surgeries (MIS), and advancements in catheter technology.
The growing demand for effective urinary drainage solutions is driven by the rising incidence of urinary tract infections (UTIs), kidney diseases, and benign prostatic hyperplasia (BPH). According to the National Kidney Foundation (2023), approximately 19.1% of males and 9.4% of females experience kidney stones by the age of 70, contributing to the demand for long-term urinary management solutions like Foley catheters. Additionally, the World Health Organization (WHO) reports that over 15 million people worldwide live with spinal cord injuries (SCI), a significant portion of whom require indwelling urinary catheters for bladder management.
The adoption of minimally invasive surgeries (MIS) has surged, as patients prefer procedures that result in smaller incisions, shorter hospital stays, and faster recovery times. Foley catheters play an essential role in MIS procedures, providing continuous bladder drainage and reducing postoperative complications. Moreover, technological advancements, including antimicrobial coatings, sensor-equipped smart catheters, and biodegradable materials, have enhanced the safety and efficacy of Foley catheters, further accelerating market growth.
Strategic collaborations and M&A activities among key industry players are shaping the competitive landscape. For instance, in December 2023, Bactiguard Holding AB partnered with BD (Becton Dickinson & Company) to distribute Bactiguard-coated Foley catheters in multiple countries, including the U.S., Canada, UK, Ireland, Japan, and Australia. These distribution agreements are expected to expand market penetration and boost revenue growth.
From a regional perspective, North America dominated the market in 2023, with a revenue share of 31.62%, due to advanced healthcare infrastructure, increasing prevalence of chronic kidney diseases (CKD), and a high aging population. However, Asia Pacific is expected to witness the fastest growth, driven by rising healthcare expenditures, rapid aging populations in China and Japan, and expanding access to urological care.